Baird analyst Brian Skorney reported no change in their view on Sarepta Therapeutic (NASDAQ: SRPT) following the dystrophin workshop. The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE